Acute upper airway disease in children with the omicron (B.1.1.529) variant of SARS-CoV-2: a report from the National COVID Cohort Collaborative (N3C)

Introduction

SARS-CoV-2 can cause severe pediatric disease including acute COVID-19 and multisystem inflammatory syndrome in children (MIS-C)¹. Published reports of SARS-CoV-2 causing laryngotracheobronchitis (commonly known as “croup”), however, have been limited to small case series². Other coronaviruses (e.g. type NL63) are known to cause croup.

The Omicron (B.1.1.529) strain of SARS-CoV-2 became dominant in the U.S. during the week of 12/25/2021³. Early reports suggest Omicron may cause lower severity disease than the Delta variant⁴. This may be because Omicron replicates less efficiently in lung parenchyma and more efficiently in the conducting airways⁵. However, these mechanistic hypotheses have not been confirmed.

Young children are especially vulnerable to acute upper airway infection (UAI) because their airways are small and relatively collapsible. Inflammation from UAI can rapidly decrease air flow. Accordingly, croup is classically an early childhood disease. We conducted this retrospective cohort study to determine if acute UAI is more common as Omicron has become the dominant U.S. SARS-CoV-2 variant.

Methods

We leveraged the National COVID Cohort Collaborative (N3C)⁶ and a pipeline we built for a NIH-funded pediatric COVID-19 dashboard (https://covid.cd2h.org/pediatrics-dashboard/) to conduct this study. Among all children in N3C <19-years-old with a positive SARS-CoV-2 test (polymerase chain reaction, antigen, or antibody), we identified those with a croup or tracheitis diagnosis. We included bacterial tracheitis because it can be difficult to distinguish from □— and can be a complication of □— viral croup. We compared groups using chi-square and Fisher exact tests for categorical variables and Mood’s Median test and t-tests for continuous variables. The N3C Data Enclave, data transfer from sites to N3C, and this analysis were approved under separate institutional review board protocols as documented elsewhere¹.

Results

SARS-CoV-2 positive UAI cases have increased as the Omicron variant has become dominant (Figure 1). During December 2021, we observed the largest monthly number thus far of hospitalized (N=32) and non-hospitalized (N=138) SARS-CoV-2 positive UAI cases. Of December 2021 hospitalizations, 2.5% (32/1302) had UAI. Overall, the 1/13/2022 N3C data release contains 15,806 hospitalized SARS-CoV-2 positive children, of whom 1.5% (234/15,806) had UAI (Table 1). Compared to those without UAI, those with UAI were more likely to be male (59.8% versus 50.4%, p=0.003), younger (2.4 versus 10.1 years, p<0.001), white (54.7% versus 43.3%, p=0.02), and have asthma (15% versus 10%, p=0.02). Children with UAI experienced severe disease (invasive ventilation, vasopressors, ECMO, or mortality) more often compared to children without UAI (31.6% versus 13.5%, p<0.001).

• Download figure
• Open in new tab

Figure 1:

This figure shows the count per month of inpatient (solid line) and outpatient/Emergency Department (dotted line) encounters with a diagnosis of croup or tracheitis for children less than 19-years old with positive SARS-CoV-2 tests in the National COVID Cohort Collaborative (N3C) January 13th, 2022 data release. The percentage of SARS-CoV-2 samples found to be the Omicron strain is from the U.S. Centers for Disease Control COVID Data Tracker, available at https://covid.cdc.gov/covid-data-tracker/#variant-proportions and accessed January 19, 2022. Triangles represent individual counts 1-19 that are censored as per N3C policy and shown as n = 19 in the figure.

Discussion

Overall, pediatric acute UAI has increased during the Omicron variant surge. Nearly a third of affected children develop severe disease. This observed clinical phenotype of pediatric infection by the Omicron variant appears to confirm recent mechanistic reports.

A limitation of this analysis is that diagnosis codes will only be present for completed hospitalizations in N3C; children who are still hospitalized are not represented.

Although many children with acute UAI are managed as outpatients, those with severe croup and/or tracheitis are at risk of cardiac arrest from rapid-onset upper airway obstruction. They may require therapies typically provided in intensive care units including frequent administration of nebulized racemic epinephrine, helium/oxygen mixtures, and intubation. While SARS-CoV-2 pediatric UAI rates are not overwhelmingly high, understanding this new clinical phenotype is important to health systems under severe strain. Anticipation of the potential for acute upper airway obstruction may guide therapeutic decision-making and hospital planning for available equipment and personnel.